MM-202: Long-Term Proteasome Inhibition in Multiple Myeloma (MM) Following an in-Class Transition (iCT) from Bortezomib-Based Induction to All-Oral Ixazomib-Lenalidomide-Dexamethasone (IRd) in the United States (US) MM-6 Community-Based Study: Subgroup Analyses of Real-World Data in Patients Aged <75 and ≥75 Years

Context: US MM-6 is investigating iCT from parenteral bortezomib-based induction to all-oral IRd in the diverse US community MM population, aiming to increase proteasome inhibitor (PI)-based treatment adherence/duration while maintaining quality of life and further improving patient outcomes. Objective: Analysis by patient age for the first 84 patients enrolled. Setting: Non-transplant-eligible newly-diagnosed MM patients with ≥stable disease after 3 cycles of bortezomib-based therapy are being enrolled across 22 US community sites to receive IRd for up to 39 28-day cycles or until progression/toxicity. Main outcome measures: Progression-free survival (not reported, data immature; enrollment ongoing). Results: At data cut-off, 47 and 37 patients aged Conclusions: This initial analysis of US MM-6 data by age suggests that by utilizing an iCT approach, long-term PI-based treatment with IRd may be feasible and tolerable in both older and younger patients, and may offer real-world patients the same improved efficacy obtained with long-term proteasome inhibition in clinical studies.